Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
GANX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Gain Therapeutics, Inc.NASDAQ: GANX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $403.51K fell 3.8% year over year, ahead of the -31.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +5.7% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -3.8% holds above the trailing-twelve-month pace of -31.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.8M USD
- Year-over-year change
- -24.6%
- 4-year CAGR
- +21.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.8M | -24.6% |
| FY2024 | 2024-12-31 | 2.39M | -26.7% |
| FY2023 | 2023-12-31 | 3.26M | +113.5% |
| FY2022 | 2022-12-31 | 1.53M | +81.9% |
| FY2021 | 2021-12-31 | 839.37K | — |
Stock-Based Compensation vs competitors
How GANX compares with its peers on the latest reported figures
- GANX's LTM Mar 2026 stock-based compensation of $1.79M is the 7th largest of the 9 companies compared; the peer median is $9.01M.
- Its year-over-year change of -31.8% is the 5th highest of 8, against a peer median of -2.0%.
- Over three fiscal years its annual growth of +5.7% compares with a peer median of -10.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $4.27B | +453006.6% | — | — |
| LTM Mar 2026 | $22.45M | -34.1% | +7.7% | 33.9% | |
| LTM Mar 2026 | $12.39M | -37.2% | -5.9% | — | |
| LTM Mar 2026 | $10.76M | -2.0% | +37.0% | 117.7% | |
| LTM Jun 2024 | $7.27M | — | -29.1% | 891.4% | |
| LTM Apr 2026 | $3.23M | +3574.0% | -47.8% | 179.0% | |
| LTM Mar 2026 | $1.79M | -31.8% | +5.7% | — | |
| LTM Mar 2026 | $465K | -90.1% | -10.6% | — | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding GANX) | $9.01M | -2.0% | -10.6% | 117.7% | |
Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.89M) | (17.59M) | (22.27M) | (20.41M) | (20.16M) |
| Depreciation & Amortization | 15.48K | 64.17K | 83.58K | 84.07K | 94.05K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 839.37K | 1.53M | 3.26M | 2.39M | 1.8M |
| Change in Working Capital | (329.78K) | 1.51M | 442.23K | (1.08M) | (1.01M) |
| Accounts Receivables | (63.35K) | 3.63K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (521.39K) | 1.07M | (643.16K) | 274.89K | (468.61K) |
| Other Working Capital | 254.96K | 444.52K | 1.09M | (1.36M) | (537.91K) |
| Other Non-Cash Items | 999.87K | (206.86K) | (383.19K) | 143.52K | 804.94K |
| Operating Cash Flow | (12.37M) | (14.69M) | (18.87M) | (18.87M) | (18.47M) |
| Capital Expenditures | (94.21K) | (118.95K) | (15.36K) | (22.49K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (17.74M) | (1.96M) | 0 | 0 |
| Sales of Investments | 0 | 3.08M | 12.19M | 5M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (94.21K) | (14.77M) | 10.22M | 4.98M | 0 |
| Debt Repayment | (21.95K) | (78.77K) | (89.07K) | (90.88K) | (96.5K) |
| Common Stock Issued | 42.63M | 0 | 12.73M | 13.21M | 28.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (841.27K) | 0 | 0 | (109.36K) | 0 |
| Financing Cash Flow | 41.77M | (78.77K) | 12.64M | 13.01M | 28.45M |
| Effect of Forex Changes | 100.78K | (23.8K) | 488.4K | (527.17K) | 469.43K |
| Net Change in Cash | 29.41M | (29.57M) | 4.49M | (1.41M) | 10.46M |
| Free Cash Flow | (12.46M) | (14.81M) | (18.88M) | (18.9M) | (18.47M) |
Gain Therapeutics, Inc.
NASDAQ:GANX
Intrinsic Alpha fair value
Locked
Current Price
$1.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.